Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors Read More
Telephus Medical Founder Awarded $6 Million NIH Grant to Expand Translational Research in Bone Infections Read More
Retrotope initiates second patient for Compassionate Use of RT001 for an ultrarare genetic neurological disease, Infantile Neuroaxonal Dystrophy. Read More
Zavante Therapeutics Presents Additional Clinical and Microbiologic Data From ZOLYD™ Phase 2/3 Trial at ID Week 2017 Read More
Zavante Therapeutics Announces Agreement With NIAID To Assess ZOLYD™ For Lower Respiratory Tract Infections Read More
Zavante Therapeutics Presents Positive Results From NIH-Sponsored ZOLYD™ Phase 1 Trial At ASM Microbe 2017 Meeting Read More
Retrotope Chairman, Dr. Harry J. Saal, highlights the ideas and concepts behind Retrotope’s technology at TEDxPaloAlto Read More
Zavante Therapeutics’ ZOLYD™ Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections Read More